Neuraxpharm and Panaxia Partner For Poland, After Germany And France
Companies Expect Sale Of Medical Cannabis-Based Product To Commence in First Half Of 2022
CNS specialist Neuraxpharm has announced expanding its strategic collaboration with Panaxia Labs Israel for advanced medical cannabis-based pharmaceutical products to Poland, after Germany and France. The companies expect sale of the cannabis portfolio to commence in the first half of 2022.
You may also be interested in...
Neuraxpharm Expands European Reach With Dutch Operation
Neuraxpharm has made its latest move into a new European market, this time opening up a new unit in the Netherlands that will be led by the firm’s German head Philipp Pohoralek as country manager.
Panaxia And Neuraxpharm Sign To Sell Medical Cannabis In The Czech Republic And Switzerland
Panaxia and Neuraxpharm have added the Czech Republic and Switzerland to their growing list of European markets for medical cannabis. Both countries have passed recent legislation to stimulate prescriptions of cannabis products.
Neuraxpharm Boosts Branded Business With Established Sanofi Portfolios
CNS specialist Neuraxpharm has purchased two of Sanofi’s product portfolios, substantially expanding the number of branded products it has to offer.